Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Shire to Forest on Deal List for AstraZeneca: Real M&A
Bloomberg
Tuesday, February 12, 2013 - 12:13pm
tags:
Shire, Forest Labs, AstraZeneca, M&A
Dynavax Options Trade for Heplisav FDA Approval Decision
TheStreet.com
Tuesday, February 12, 2013 - 12:12pm
tags:
FDA, Dynavax, Heplisav
Alimera Sciences: A Sleeping Giant
Seeking Alpha
Tuesday, February 12, 2013 - 12:06pm
tags:
Alimera, diabetic macular edema, flucinolone ocular implant
GSK, others weigh $3-4 billion deal for Brazilian drugmaker: sources
Reuters
Tuesday, February 12, 2013 - 12:04pm
tags:
GSK, M&A, Brazil, Ache Laboratorios Farmaceuticos
Update on Lilly's Tabalumab
Yahoo/Zacks
Tuesday, February 12, 2013 - 11:12am
tags:
Eli Lilly, tabalumab, rheumatoid arthritis
Will Johnson & Johnson Win Approval for Its Diabetes Drug?
Motley Fool
Tuesday, February 12, 2013 - 11:00am
tags:
JNJ, diabetes, Invokana
Why Raptor Could Run Up To Its PDUFA
Seeking Alpha
Tuesday, February 12, 2013 - 10:59am
tags:
Raptor Pharmaceuticals, Mylan, nephropathic cystinosis, RP103
Can This Celgene Drug Defy the Patent Cliff?
Motley Fool
Tuesday, February 12, 2013 - 10:57am
tags:
patents, Celgene, myelodysplastic syndrome, Vidaza
Eli Lilly says will keep animal health business, Reuters reports
Yahoo/Fly on the Wall
Tuesday, February 12, 2013 - 10:55am
tags:
animal health, Eli Lilly, Elanco
Amgen, UCB halt testing of drug for fracture healing, but continue testing for osteoporosis
Yahoo/AP
Tuesday, February 12, 2013 - 10:55am
tags:
Amgen, UCB Pharmaceuticals, fractures, osteoporosis, romosozumab
Reckitt in $482 mln deal to sell Bristol drugs in LatAm
Reuters
Tuesday, February 12, 2013 - 10:54am
tags:
Reckitt Benckiser, Latin America, M&A, Bristol-Myers Squibb, OTC
J&J’s Marketer E-Mailed Hip Safety Concerns Before Recall
Bloomberg
Tuesday, February 12, 2013 - 10:52am
tags:
hip implants, recalls, JNJ, DePuy
U.S. court invalidates patent on Bristol hepatitis B drug
Reuters
Tuesday, February 12, 2013 - 10:46am
tags:
Bristol-Myers Squibb, hepatitis B, Baraclude, patents
Backed By Large Pharma And Key Investors, Pharmacyclics Is Set To Climb Higher
Seeking Alpha
Monday, February 11, 2013 - 11:18am
tags:
Pharmacyclics, JNJ
Endo Seen Boosted by Fidelity-Favored Sale: Real M&A
Bloomberg
Monday, February 11, 2013 - 11:14am
tags:
M&A, Endo Health Solutions, Teva, Covidien
2 Stem Cell Research Pioneers And Where They Are Today
Seeking Alpha
Monday, February 11, 2013 - 11:12am
tags:
stem cells, BioTime, Geron, Advanced Cell Technology
Six Things to Watch at Biotech CEO Conference
Minyanville
Monday, February 11, 2013 - 11:10am
tags:
BIO CEO Conference, ONYX Pharmaceuticals, Celgene, Gilead, Biomarin, Eli Lilly, Keryx, Arena Pharmaceuticals, Orexigen
Regeneron shares jump on Sanofi share buy plan
Marketwatch
Monday, February 11, 2013 - 11:08am
tags:
Sanofi, Regeneron
Sanofi advances after FDA delays rival insulin product
The Fly on the Wall
Monday, February 11, 2013 - 11:07am
tags:
FDA, insulin, Novo Nordisk, Sanofi, Tresiba, Lantus
Can Johnson & Johnson Cash In on Stelara?
Motley Fool
Monday, February 11, 2013 - 8:23am
tags:
Stelara, JNJ, anti-inflammatories

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.